NASDAQ$GRCE

Grace Therapeutics Inc · Q2 2026 earnings

Q2 2026 earnings · · Before market open · Investor relations

Briefing

GRCE Q2 2026 — extraction skipped

Grace Therapeutics Inc filed Form 10-Q/A (accession 0001140361-25-042491) for Q2 2026, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.

  • Form 10-Q/A filed; press release body not parseable here.
  • Reason: no headline numerics found by parser nor by Financial Datasets fallback.
  • Numerics rely on the Financial Datasets fallback.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.06

Previous: -$0.30+80.0%

Revenue & EPS history

Acasti Pharma · Revenue · Quarterly

$0

Q2 2026

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 16 quarterly earnings reports · overlaid with Q2 2026

Historical avgQ2 2026

+0.7%

Avg return

Earnings day

+31.8%

Avg return

5 days after

+22.6%

Avg return

30 days after

44%

7 / 16 earnings

Positive

+12.3%

Q3 2022

Best reaction

-5.3%

Q4 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+2.3%+4.3%+9.2%
Q1 2026+3.5%+5.2%+3.9%
Q4 2025-2.3%-1.0%+11.7%
Q4 2024+1.6%-3.6%+9.4%
Q3 2025+0.0%-1.7%-37.4%
Q1 2025-1.0%-11.7%-16.5%
Q2 2025+3.8%-0.9%+12.2%
Q3 2024-1.2%+34.7%+38.8%
Q2 2024-2.0%-2.3%-4.5%
Q1 2024-1.9%+17.0%-22.0%
Q4 2023-5.3%-7.0%-25.7%
Q3 2022+12.3%-1.6%-28.1%
Q2 2022-3.6%-14.0%-30.0%
Q4 2022-3.2%+491.2%+471.7%
Q3 2021+7.0%+3.5%-10.5%
Q1 2022+1.7%-3.4%-20.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro